Elena V. Melekhina

Elena V. Melekhina

Auto-generated profile, based on publicly available information

Elena V. Melekhina

ФБУН ЦНИИ эпидемиологии Роспотребнадзора

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
MFMarina Vladislavovna Fedoseenko
Marina Vladislavovna Fedoseenko
FSFiruza Ch. Shakhtakhtinskaya
Firuza Ch. Shakhtakhtinskaya
TKTatiana A. Kaliuzhnaia
Tatiana A. Kaliuzhnaia
MSMargarita Soloshenko
Margarita Soloshenko
KOKhadizhat G. Omarova
Khadizhat G. Omarova
The pandemic caused by the new coronavirus infection remains the topical health issue and constitutes serious threat to the entire world. Nowadays, active immunization against new type of coronavirus infection continues in Russian Federation and in all other countries. Vaccination is the crucial component in comprehensive program for COVID-19 prevention and control. Mass immunization of population can prevent both admissions and hospitalization in conditions of high incidence of COVID-19 and thereby reduce the burden on the health system. Despite the remaining complications in combating the SARS-CoV-2 pandemic, preventive vaccination is by far the most effective method for protection against this infection Clinical studies on the efficacy of various preventive vaccinations in different regions of the world are extremely relevant especially under conditions of the emergency use authorization for vaccines against new coronavirus infection, the changing epidemiological situation, and the wide variability of different types of vaccines. All countries will need continuously updated data on vaccine efficacy to address new challenges such as weakening post-vaccine protection, new SARS-CoV-2 strains, and need for other preventive measures to mitigate the pandemic.

24 November 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AGA. V. Gorelov
A. V. Gorelov
ЕMЕ. V. Melekhina
Е. V. Melekhina
ЭСЭ. С. Сидельникова
Э. С. Сидельникова
The purpose of the study: to evaluate the protective properties of a multi-strain probiotic in the development of gastrointestinal disorders with impaired microbiota during antibiotic therapy (ABT) for 1 to 3 years old children with acute respiratory infection (ARI). Objectives of research: to evaluate the incidence of development and severity of gastrointestinal disorders, as well as changes in the dynamics of intestinal microbiota using 16S rRNA gene sequencing in 1 to 3 years old children with ARI and receiving ABT, depending on the addition of a multi-strain probiotic to the treatment regimen. Materials and methods: the study involved 148 children from 1 to 7 years old both girls and boys (54 children were 1 to 3 y.o. and 65 were 3 to 7 y.o.), hospitalized within first 3 days of URTI symptoms (acute upper respiratory tract infection – URTI) and 29 healthy children from outpatient department as a healthy control. Present article covers data and outcomes of younger age group – 54 children 1 to 3 years old, hospitalized within first 3 days of illness and 10 healthy children of the same age range. The main group included 27 children who received ABT + multi-strain probiotic Bac-Set® Baby for the entire period of ABT and extra 14 days after its discontinuation; the comparison group included 27 children who received only ABT. The frequency of bowel movements was assessed, feces were evaluated accordingly to Bristol scale upon admission to the hospital, befor e discharge from the hospital (in 7 ± 2 days), and in 21 ± 2 days from the beginning of ABT. Results. The frequency of bowel movements after 7 ± 2 days and 21 ± 2 days from the start of therapy was significantly higher in the comparison group than in the main group (81.5% and 26% versus 7.4% and 7.4%, respectively). The stool rate accordingly to Bristol scale in the comparison group changed up to moderate diarrhea, which was not registered in the main group. In both groups, an increase in alpha-diversity of microbiota was observed within 2-week period after discontinuation of antibiotic therapy. During the study, adverse reactions of multi-strain probiotic were not found. Conclusions. The results allow to suggest that the use of Bac-Set® Baby multistrain probiotic helps to maintain the stability of the microbiome during antibiotic therapy and in the recovery period after it. The use of Bac-Set® Baby with antibacterial therapy has a protective effect on gastrointestinal upsets incidence rate and reduces the negative impact on microbiome.

6 April 2019 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
MLM. Yu. Lysenkova
M. Yu. Lysenkova
EME. V. Melekhina
E. V. Melekhina
NKN. V. Karazhas
N. V. Karazhas
OSOksana Svitich
Oksana Svitich
ПВП. А. Веселовский
П. А. Веселовский
MIMarina Ivanova
Marina Ivanova
Клинико-эпидемиологические особенности ВГЧ-6А- и ВГЧ-6В-инфекции у детей г. Москвы

1 January 2020 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
AGA.V. Gorelov
A.V. Gorelov
EKE.V. Kanner
E.V. Kanner
ЕMЕ.V. Melekhina
Е.V. Melekhina
ESE.S. Sidelnikova
E.S. Sidelnikova

14 June 2018 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
MMMelekhina E.V. Melekhina
Melekhina E.V. Melekhina
LLLysenkova M.YU. Lysenkova
Lysenkova M.YU. Lysenkova
OSOksana Svitich
Oksana Svitich
MMMuzyka A.D. Muzyka
Muzyka A.D. Muzyka
KKKarazhas N.V. Karazhas
Karazhas N.V. Karazhas
GGGorelov A.V. Gorelov
Gorelov A.V. Gorelov

1 January 2023 in Russian Medical Inquiry
Verified
Journal Article
Open access
EME.V. Melekhina
E.V. Melekhina
KHKhimki Khimki Regional Hospital
Khimki Khimki Regional Hospital
DPD.V. Preobrazhenskaia
D.V. Preobrazhenskaia
AMA.D. Muzyka
A.D. Muzyka
ESE.Yu. Soldatova
E.Yu. Soldatova
AGA.V. Gorelov
A.V. Gorelov
Background: recurrent respiratory infections (RRI) in children are a relevant medical and social issue. Reactivation of latent herpes simplex virus (HSV) infections is recognized as one of the leading causes of recurrent respiratory infections. Its rate in children is up to 40%. Therapeutic options for recurrent respiratory infections in children are discussed given the activity of HSV infections and immune disorder treatment. Aim: to assess the efficacy of inosine pranobex (Normomed®) for recurrent respiratory infections and active HSV infection in children. Patients and Methods: we examined 96 children aged 1–17 years who requested medical care in an outpatient department with complaints typical of recurrent respiratory infections and laboratory-confirmed active HSV infection. Children received inosine pranobex (50–75 mg/kg/day) in three 10-day courses (10-day breaks). 5±1 weeks after finishing therapy, control clinical and laboratory tests and virology were performed. The nature of ARI episodes during the follow-up period and HSV infection activity over time were evaluated. Results: during treatment, a reduction in the rate and severity of respiratory diseases was reported in 94% of children. Fever severity decreased twice (p=0.035), oropharynx condition improved in 66.7% (p<0.01), and the severity of lymphoproliferative syndrome reduced in 62.5% (tonsil hypertrophy in 52.1%, lymphadenopathy in 50.6%, hepatomegaly in 55.3%, splenomegaly in 66.7%). During treatment with inosine pranobex, a decrease in HSV infection activity was reported in 88.6% of children. The active HSV count also decreased. A significant (p<0.01) reduction in the percentage of patients with active HHV 6A/B (from 78.1% to 12.5%), Epstein– Barr virus (from 45.8% to 7.3%), and HSV type 1 (from 14.6% to 1.0%) was reported. Conclusion: significant improvement in the somatic and virological status of children with recurrent respiratory infections and HSV infection after a course of inosine pranobex, which is characterized by antiviral and immunomodulatory effects, was established. KEYWORDS: monthly respiratory infections, recurrent respiratory infections, Epstein–Barr virus, human herpes virus 6A/B, children, inosine pranobex, Normomed. FOR CITATION: Melekhina E.V., Preobrazhenskaia D.V., Muzyka A.D., Soldatova E.Yu., Gorelov A.V. Recurrent respiratory infections and active herpesvirus infections in children: problems and solutions. Russian Medical Inquiry. 2023;7(11):704–712 (in Russ.). DOI: 10.32364/2587- 6821-2023-7-11-2.